Clinical trials: Gefitinib
Brain and Central Nervous System Tumors, Prostate Cancer
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
RATIONALE: Everolimus may stop the growth of tumor cells by stopping blood flow to the tumor. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
- Trial name
- NCT00085566
- Testing
- everolimus, gefitinib
- Where
- 2 sites in United States, Spain
- Volunteers
- 61 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-squamous, Non-Small Cell Lung Cancer
The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib
Non-interventional, multi-country, multi-centre cohort study based on existing data from medical records (paper or electronic) or electronic health records of patients with advanced NSCLC harbouring EGFR mutations and treated…
- Trial name
- UpSwinG (NCT04179890)
- Testing
- Afatinib (Gi(l)otrif®), Erlotinib (Tarceva®), Gefitinib (IRESSA®)
- Where
- United Kingdom
- Volunteers
- 462 people
- Sponsor
- Boehringer Ingelheim
Non-Small Cell Lung Cancer
Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP)
The purpose of the study is to determine patient characteristics from patients that have used Iressa for a period of minimal 3 years.
- Trial name
- NCT01103089
- Where
- 11 sites in Netherlands
- Volunteers
- 10 people
- Sponsor
- AstraZeneca
Non-Small Cell Adenocarcinoma, Tyrosine Kinase Mutation
Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma
Treatment for patients with mutation in the epidermal growth factor receptor (EGFR) with specific domain tyrosine kinase inhibitors (TKIs) has given place to objective clinical response, increase in progression-free survival…
- Conditions
- Non-Small Cell Adenocarcinoma, Tyrosine Kinase Mutation, EGFR Gene Mutation
- Trial name
- NCT03071705
- Testing
- Metformin, TKI
- Where
- Mexico
- Volunteers
- 120 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Prostate Cancer
Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy
To evaluate activity of gefitinib in subjects with relapsed prostate cancer by estimating PSA response rate at study closure
- Trial name
- NCT00241475
- Testing
- Gefitinib
- Where
- Finland
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Non-Small-Cell Lung Carcinoma
Anticancer Activity of Nicotinamide on Lung Cancer
Nicotinamide is an inhibitor of human sirtuins (HDAC III), and is found to re-activate epigenetically silenced tumor suppressors, RUNX3 (runt-related gene 3) and others, in cancer cells.
- Trial name
- NCT02416739
- Testing
- Nicotinamide
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- Il Yeong Park, Ph.D.
Breast Cancer
ZD1839 (Iressa™) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer
This is a multicentre, randomised (2:1), double blind, non-comparative phase II trial of ZD1839 and placebo in combination with chemotherapy in patients with metastatic breast cancer.
- Trial name
- NCT00247481
- Testing
- Gefitinib, Docetaxel
- Where
- 5 sites in France
- Volunteers
- 77 people
- Sponsor
- AstraZeneca
Breast Cancer
A Feasibility Study With Iressa in Resistant Cytokeratin-Positive Tumor Cells Circulating in the Blood of Women With Breast Cancer
Based on preclinical data, ZD1839 is considered a novel and promising therapeutic approach with potential application in the treatment of human breast cancer.
- Trial name
- NCT00428896
- Testing
- ZD1839
- Where
- Greece
- Volunteers
- 24 people
- Sponsor
- University Hospital of Crete
Lung Cancer
Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.
Here we are going to find a method by using available multiple drugs including angiogenesis medicine - Endostar to treat lung cancer patients who acquired resistence from EGFR-TKI but have responsed to it before.
- Trial name
- NCT02350361
- Testing
- Recombinant human endostatin
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Third Hospital
Non-small-cell Lung Cancer
ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer
The primary objective of this study is to examine if the combination regimen of ARQ 197 with erlotinib is active in subjects with locally advanced or metastatic NSCLC with activating mutation EGFR who progressed on EGFR-TKI…
- Trial name
- NCT01580735
- Testing
- ARQ 197
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Lung Cancer
Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as sirolimus, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00098462
- Testing
- gefitinib, sirolimus
- Sponsor
- Jonsson Comprehensive Cancer Center
Non-Small Cell Lung Cancer
CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung Cancer
Lung cancer is the most common cancer worldwide, non-small cell lung cancer (NSCLC) comprises about 85% of all lung cancer cases, which is the leading cause of cancer mortality, and adenocarcinoma is the most prevalent subtype.
- Trial name
- NCT01871480
- Testing
- Group A:cytokine-induced killer cell +gefitinib, Group B:Gefitinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Kunming Medical University
Lung Cancer
Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases
Patients will receive AZD9291 at a dose of 80 mg once daily. Intracranial response will be assessed with brain MRI scan, systemic evaluation will be done by PET-CT (Positron Emission Tomography-Computed Tomography) scan.
- Trial name
- NCT02736513
- Testing
- AZD9291
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Soroka University Medical Center
Non-small Cell Lung Cancer (NSCLC), EGFR-TKI Resistant Mutation
A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
For patients of advanced NSCLC (non small cell lung cancer) , Individualized cancer therapy has been widely accepted since the success of crizotinib administration based on EML4-ALK fusion gene detection and gefitinib and…
- Conditions
- Non-small Cell Lung Cancer (NSCLC), EGFR-TKI Resistant Mutation, EGFR-TKI Sensitizing Mutation, Germline Mutations
- Trial name
- NCT01994057
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Non-Small-Cell Lung
Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
This is a randomized, open- label, parallel group, phase IV, multicentre study. The total number of patients expected to be recruited is 40.
- Trial name
- NCT00536107
- Testing
- Gefitinib, CT or MRI, Docetaxel
- Where
- Taiwan
- Volunteers
- 14 people
- Sponsor
- AstraZeneca
Lung Cancer
First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker
The investigators will conduct the randomized trial to determine the role of Gefitinib monotherapy as first-line setting in adenocarcinoma patients with no history of smoking, as compared with the standard combination…
- Trial name
- NCT00455936
- Testing
- Gefitinib, chemotherapy
- Where
- 3 sites in South Korea
- Volunteers
- 315 people
- Sponsor
- National Cancer Center, Korea
NSCLC, EGFR Gene Amplification
Combination of Metformin With Gefitinib to Treat NSCLC
The purpose of this study is to determine whether metformin in combination with gefitinib are effective in patients with previously untreated advanced or metastatic Non-Small-Cell Lung cancer with epidermal growth factor receptor…
- Conditions
- NSCLC, EGFR Gene Amplification, Advanced Cancer, Stage IIIB NSCLC
- Trial name
- CGMT (NCT01864681)
- Testing
- Gefitinib and Metformin
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Breast Neoplasms
Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer
The purpose of this study is to learn how breast cancer tumors respond to treatment combining the drugs docetaxel and ZD1839.
- Trial name
- NCT00052169
- Testing
- ZD1839 in combination with docetaxel
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- NSABP Foundation Inc
Non-Small-Cell Lung Carcinoma
Phase II Iressa Versus Vinorelbine (INVITE)
This is a randomized, open label, parallel group, multi-centre, phase II study of progression free survival, comparing oral ZD1839 (IRESSA™) (250 mg tablet once daily) to vinorelbine 30 mg/m2 infusion on days 1 and 8 of a 21-day…
- Trial name
- NCT00256711
- Testing
- Gefitinib, Vinorelbine
- Where
- 55 sites in Australia, Brazil and 8 more
- Volunteers
- 192 people
- Sponsor
- AstraZeneca
NSCLC
De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
This study is based on the following hypothesis "De novo resistance to EGFR-TKI in EGFR mutation positive patients is related with mutations in EGFR downstream genes".
- Trial name
- NCT01697163
- Volunteers
- 155 people
- Sponsor
- Severance Hospital